Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Travere Therapeutics reports robust earnings, eyes market expansion opportunities

Travere Therapeutics is on a solid financial footing with promising drug launches and clinical advancements. While facing regulatory and competitive challenges, the company's strategic focus on market expansion and product utilization presents significant growth opportunities. With a strong cash position and ongoing clinical developments, Travere is well-positioned for future success.

Travere Therapeutics reports strong Q1 performance amidst FILSPARI launch

Travere Therapeutics' Q1 performance was driven by strong FILSPARI sales and positive physician adoption.
Despite challenges in FSGS and HCU programs, regulatory flexibility and patient community evolution present opportunities.
Physician interest in FILSPARI data and payer coverage quality are key strengths for the successful launch.
Monitoring metrics and upcoming study readouts offer avenues for growth and optimization in rare disease treatments.

Travere Therapeutics reports strong Q2 performance and growth opportunities

Travere Therapeutics showcased strong performance with revenue growth and positive clinical results across key programs.
The company's strategic focus on core pipeline programs and divestment of non-core assets has bolstered its financial position.
Challenges include competitive dynamics, regulatory uncertainties, and the need for disciplined spending amidst growth opportunities.
Overall, Travere is well-positioned for future growth with promising pipeline programs and a focus on market expansion.

Travere Therapeutics reports strong Q3 performance and strategic advancements

Travere Therapeutics showcased strong operational and financial performance in Q3 2023, with advancements in key programs and positive regulatory engagements.
The company's strategic focus on rare disease treatments, patient education efforts, and regulatory alignment position it well for future growth.
Challenges in revenue forecasting, market positioning, and evolving treatment landscapes highlight areas for ongoing strategic focus and adaptation.
Opportunities in market expansion, revenue growth, program advancements, and patient engagement present avenues for continued success and impact.

Travere Therapeutics reports strong revenue growth and strategic advancements

Travere Therapeutics had a successful year with strong revenue growth and progress in key treatments
Filspari's performance in IgAN drove demand and revenue, positioning the company for further growth
Challenges include the DUPLEX study results and low innovation in the prescriber base
Opportunities lie in sNDA submissions, ongoing studies, and potential for full approval and broader label

Travere Therapeutics excels in Q1 with FILSPARI market success

Travere Therapeutics showcased strong performance and financial stability in Q1 2024, driven by FILSPARI's successful commercial launch and positive patient outcomes.
The company's focus on market adoption, regulatory milestones, and engagement strategies positions it for continued growth and potential inclusion in treatment guidelines.
Challenges in inventory management, regulatory compliance, and strategic alignment with stakeholders need to be addressed to capitalize on growth opportunities and maintain market leadership.

Travere Therapeutics excels in Q2 2024, poised for growth

Travere Therapeutics delivered a strong performance in Q2 2024, driven by FILSPARI's growth and positive regulatory developments.
While facing challenges in regulatory processes and market expansion, the company's solid financial position and ongoing initiatives position it well for future success.
Opportunities for growth abound through potential approvals, global expansion, and advancements in drug development programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ST. GALLEN, Switzerland & SAN DIEGO, Calif.--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand. Sparsentan is a novel investigational product candidate currently being evaluated in pivotal phase-III clinical studies for the treatment of

Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand

Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand

Ms. Williams-Brinkley brings more than 35 years of executive leadership experience in healthcare to the Travere Board Ms. Williams-Brinkley brings more than 35 years of executive leadership experience in healthcare to the Travere Board

Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors

Travere Therapeutics Inc (NASDAQ: TVTX) has concluded a Type A meeting with the FDA related to sparsentan in focal segmental glomerulosclerosis (FSGS).  See:   Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More Data.

See Why Travere Therapeutics Stock Moving Higher On Tuesday

Shares of Travere Therapeutics remain well below this year's highs despite PROTECT study success. The regulatory update on the FSGS indication of sparsentan has weighed on the share price along with the poor biotech sentiment.

Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success

Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises

Travere (TVTX) Announces Data on Rare Kidney Disease Drug

Investors are cheering positive phase 3 trial results with sparsentan that suggest it could become an important new treatment for a rare kidney disease.

Here's Why Travere Therapeutics Stock Is Climbing Today

Travere Therapeutics (TVTX) stock is on the rise Monda and it's all thanks to positive interim results from one of its clinical trials. The post TVTX Stock: Why Travere Therapeutics Stock Is Rocketing Higher Today appeared first on InvestorPlace.

TVTX Stock: Why Travere Therapeutics Stock Is Rocketing Higher Today

Compared to the active control irbesartan, the study met its pre-specified interim primary efficacy endpoint, demonstrating a more than threefold reduction of proteinuria from baseline after 36 weeks of treatment.  After 36 weeks of treatment, patients receiving sparsentan achieved a mean reduction in proteinuria from a baseline of 49.8%, compared to 15.1% for irbesartan-treated patients.

Travere Therapeutics Stock Is Trading Higher On Positive Data From Kidney Disease Candidate

The shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) increased by over 30% pre-market. This is why it happened.

Travere Therapeutics Shares Increase Over 30% Pre-Market: Why It Happened

Travere Therapeutics, Inc. (TVTX) CEO Dr. Eric Dube on Q2 2021 Results - Earnings Call Transcript

Shares of Travere Therapeutics (NASDAQ:TVTX) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 77.27% over the past year to ($0.39), which beat the estimate of ($0.68).

Travere Therapeutics: Q2 Earnings Insights

Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021

Travere Therapeutics Reports Second Quarter 2021 Financial Results

Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Travere Therapeutics (TVTX) Q2 Earnings Expected to Decline

SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Travere Therapeutics to Report Second Quarter 2021 Financial Results

Travere suffered two major setbacks recently. The stock is trading at 52-week lows as a result.

Travere: Setback Presents Cautious Opportunity

The FDA quashes the company's hopes for accelerated approval of a key pipeline drug.

Why Travere Therapeutics Stock Is Plummeting Today

Following the pre-NDA meeting, the FDA has asked Travere Therapeutics Inc (NASDAQ: TVTX) to submit additional data for the sparsentan program in focal segmental glomerulosclerosis (FSGS), characterized by scarring (sclerosis) in the kidney. The agency indicated that the available data from the interim assessment of the DUPLEX Phase 3 study would not be adequate to support an accelerated approval at this time.

Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More Data

Conference call and webcast to be held at 4:30p.m. ET Conference call and webcast to be held at 4:30p.m. ET

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q1 2021 Results - Earnings Call Transcript

Earnings Preview: Travere Therapeutics (TVTX) Q1 Earnings Expected to Decline

SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 5:00 p.m. ET.

Travere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Travere Therapeutics to Report First Quarter 2021 Financial Results

Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q4 2020 Results - Earnings Call Transcript

Travere (TVTX) delivered earnings and revenue surprises of -451.16% and -0.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Travere Therapeutics Stock (TVTX)